(2R)-2-苯基哌嗪 | 137766-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (2R)-2-苯基哌嗪
• 中文别名: (2R)-2-苯基哌
• 英文名称: (R)-2-phenylpiperazine
• 英文别名: (2R)-2-phenylpiperazine
• CAS: 137766-76-8
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: RIMRLBGNCLMSNH-JTQLQIEISA-N

物化性质

• 沸点：
  289.2±25.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R)-2-苯基哌嗪 在 sodium triacetylborohydride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium t-butanolate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 3.0h， 生成 tert-butyl (R)-2-(((R)-4-(4-(tert-butyldimethylsiloxy)phenyl)-2-phenylpiperazin-1-yl)methyl)pyrrolidin-1-carboxylate
  参考文献：
  名称：

  组蛋白去甲基化酶LSD1抑制剂

  摘要：

  组蛋白去甲基化酶LSD1抑制剂，本发明涉及式I的含哌嗪类化合物或其药学上可接受的盐及其作为LSD1抑制剂的用途:I，本发明属于药物化学领域。体外LSD1活性抑制试验表明，本发明所列举的哌嗪类化合物对LSD1活性具有明显的抑制作用，可以将其作为活性成分用于制备LSD1抑制剂药物。

  公开号：

  CN107176927B
• 作为产物：
  描述：

  (R)-3-phenylpiperazine-2,5-dione 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以1.1g的产率得到(2R)-2-苯基哌嗪
  参考文献：
  名称：

  组蛋白去甲基化酶LSD1抑制剂

  摘要：

  组蛋白去甲基化酶LSD1抑制剂，本发明涉及式I的含哌嗪类化合物或其药学上可接受的盐及其作为LSD1抑制剂的用途:I，本发明属于药物化学领域。体外LSD1活性抑制试验表明，本发明所列举的哌嗪类化合物对LSD1活性具有明显的抑制作用，可以将其作为活性成分用于制备LSD1抑制剂药物。

  公开号：

  CN107176927B

文献信息

• Benzo[1,8]naphthyridine derivatives, their preparation and compositions
  申请人：Laboratoire Roger Bellon

  公开号：US05053509A1

  公开（公告）日：1991-10-01

  New benzo[b][1,8]naphthyridine derivatives of general formula (I), in which R.sub.1 is a hydrogen atom or a hydroxyl or alkyl radical, R.sub.2 is a hydrogen atom or an alkyl, fluoroalkyl, cycloalkyl (3 to 6 C), alkyloxy or alkylamino radical, R.sub.3 is a phenyl or phenylalkyl radical substituted with one or more halogen atoms or alkyl, cycloalkyl (3 to 6 C), alkyloxy, cyano, amino, alkylamino, dialkylamino, alkyloxyalkyl, hydroxyalkyl, hydroxyalkyloxy, methylenedioxy, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radicals, or R.sub.3 is a heterocyclic radical, and R.sub.4 is a hydrogen atom or a fluorine atom, the alkyl radicals (1 to 4 C) being linear or branched, their salts, their preparation and compositions containing them. These new products are useful as antimicrobials, or in the treatment of AIDS. ##STR1##

  新的苯并[b][1,8]萘啉衍生物的一般式(I)，其中R.sub.1是氢原子或羟基或烷基基团，R.sub.2是氢原子或烷基、氟烷基、环烷基（3至6个碳）、烷氧基或烷基氨基基团，R.sub.3是苯基或苯基烷基基团，其上取代有一个或多个卤素原子或烷基、环烷基（3至6个碳）、烷氧基、氰基、氨基、烷基氨基、二烷基氨基、烷氧基烷基、羟基烷基、羟基烷氧基、亚甲二氧基、氨基烷基、烷基氨基烷基或二烷基氨基烷基基团，或R.sub.3是杂环基团，R.sub.4是氢原子或氟原子，烷基基团（1至4个碳）为直链或支链，它们的盐、它们的制备和含有它们的组合物。这些新产品可用作抗微生物药物，或用于治疗艾滋病。
• Biocatalytic Access to Piperazines from Diamines and Dicarbonyls
  作者：Niels Borlinghaus、Sebastian Gergel、Bettina M. Nestl

  DOI：10.1021/acscatal.8b00291

  日期：2018.4.6

  Given the widespread importance of piperazines as building blocks for the production of pharmaceuticals, an efficient and selective synthesis is highly desirable. Here we show the direct synthesis of piperazines from 1,2-dicarbonyl and 1,2-diamine substrates using the R-selective imine reductase from Myxococcus stipitatus as biocatalyst. Various N- and C-substituted piperazines with high activity and excellent

  考虑到哌嗪作为生产药物的基础材料的广泛重要性，非常需要有效和选择性的合成。在这里，我们显示了使用来自粘球菌的R-选择性亚胺还原酶作为生物催化剂，从1,2-二羰基和1,2-二胺底物直接合成哌嗪的方法。在温和的反应条件下获得了高达每升8.1克的各种具有高活性和优异对映选择性的N和C取代的哌嗪。
• Sorbitol dehydrogenase inhibitors
  申请人：Pfizer Inc.

  公开号：US06414149B1

  公开（公告）日：2002-07-02

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2 and R3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

  本发明涉及式I的山梨醇脱氢酶抑制化合物，其中R1、R2和R3如规范中定义。本发明还涉及含有这些化合物的药物组合物，以及通过向患有糖尿病且因此有发展这些并发症风险的哺乳动物投与这些化合物来治疗或预防糖尿病并发症，特别是糖尿病神经病变、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病。本发明还涉及一种含有本发明式I化合物与醛糖还原酶抑制剂的组合物的药物组合物，以及用于治疗或预防糖尿病并发症的方法。本发明还涉及一种含有本发明式I化合物与NHE-1抑制剂的组合物的药物组合物，以及用于治疗心肌病和其他相关心脏问题的方法。本发明还涉及合成式I化合物的某些中间体以及制备这些中间体的方法。
• [EN] BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE BROMODOMAINES BET BICYCLIQUES ET LEURS UTILISATIONS
  申请人：STROVEL JEFFREY WILLIAM

  公开号：WO2017091661A1

  公开（公告）日：2017-06-01

  The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.

  本发明涉及结合并调节含有溴结构域蛋白的化合物，制备这些化合物的方法，含有这些化合物的药物组合物，以及使用这些化合物治疗各种疾病和疾病的方法。
• [EN] AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS<br/>[FR] AMINOPYRIMIDINES COMME INHIBITEURS DE SORBITOL DESHYDROGENASE
  申请人：PFIZER PROD INC

  公开号：WO2000059510A1

  公开（公告）日：2000-10-12

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of formula (I), wherein R?1, R2 and R3¿ are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefor at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula (I) of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula (I) of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula (I) and to processes for preparing those intermediates.

  本发明涉及式（I）的山梨醇脱氢酶抑制剂，其中R1、R2和R3在说明书中定义。本发明还涉及含有这些化合物的药物组合物，以及通过将这些化合物用于患有糖尿病并因此有患上这些并发症风险的哺乳动物进行治疗或预防糖尿病并发症，特别是糖尿病神经病变、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病的方法。本发明还涉及一种包含本发明式（I）化合物和醛还原酶抑制剂的药物组合物以及用于治疗或预防糖尿病并发症的方法。本发明还涉及一种包含本发明式（I）化合物和NHE-1抑制剂的药物组合物以及用于治疗心肌病和其他心脏相关问题的方法。本发明还涉及用于合成式（I）化合物的某些中间体以及制备这些中间体的方法。